 Michael McDermott
Concepts (149)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hyperthyroidism | 5 | 2020 | 26 | 1.790 |
Why?
| | Hypothyroidism | 5 | 2020 | 65 | 1.700 |
Why?
| | Graves Disease | 2 | 2020 | 32 | 0.780 |
Why?
| | Osteoporosis | 5 | 2009 | 227 | 0.760 |
Why?
| | Triiodothyronine | 3 | 2020 | 43 | 0.750 |
Why?
| | Thyroid Neoplasms | 2 | 2020 | 262 | 0.740 |
Why?
| | Thyroxine | 3 | 2020 | 59 | 0.670 |
Why?
| | Bone Density Conservation Agents | 2 | 2009 | 62 | 0.600 |
Why?
| | Thyroid Diseases | 4 | 2005 | 30 | 0.590 |
Why?
| | Hypoglycemic Agents | 2 | 2016 | 1008 | 0.570 |
Why?
| | Thyrotoxicosis | 2 | 2020 | 8 | 0.560 |
Why?
| | Vitamins | 2 | 2008 | 151 | 0.550 |
Why?
| | Vitamin D | 3 | 2008 | 341 | 0.530 |
Why?
| | Antithyroid Agents | 4 | 2020 | 11 | 0.530 |
Why?
| | Iodine Radioisotopes | 4 | 2020 | 126 | 0.500 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2012 | 43 | 0.400 |
Why?
| | Thyrotropin | 4 | 2020 | 100 | 0.390 |
Why?
| | Vitamin D Deficiency | 3 | 2009 | 159 | 0.380 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2016 | 2098 | 0.380 |
Why?
| | Diagnosis, Differential | 4 | 2020 | 1357 | 0.360 |
Why?
| | Premenopause | 1 | 2009 | 103 | 0.320 |
Why?
| | Patient Education as Topic | 2 | 2015 | 686 | 0.310 |
Why?
| | Thyroidectomy | 2 | 2020 | 52 | 0.280 |
Why?
| | Thyroid Hormones | 2 | 2020 | 53 | 0.270 |
Why?
| | Endocrinology | 2 | 2004 | 69 | 0.270 |
Why?
| | Pharmacists | 1 | 2008 | 237 | 0.260 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 1724 | 0.250 |
Why?
| | Hormone Replacement Therapy | 2 | 2020 | 77 | 0.250 |
Why?
| | Bone Density | 4 | 2009 | 432 | 0.250 |
Why?
| | Hospitalization | 2 | 2020 | 1765 | 0.240 |
Why?
| | Humans | 28 | 2020 | 115612 | 0.230 |
Why?
| | Reproductive Medicine | 1 | 2004 | 15 | 0.230 |
Why?
| | Professional Practice | 1 | 2003 | 63 | 0.220 |
Why?
| | Blood Glucose | 2 | 2016 | 1824 | 0.220 |
Why?
| | Thyrotropin, beta Subunit | 1 | 2002 | 5 | 0.220 |
Why?
| | Insulin | 2 | 2016 | 2082 | 0.210 |
Why?
| | Drug Therapy, Combination | 2 | 2020 | 962 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2008 | 906 | 0.200 |
Why?
| | Point Mutation | 1 | 2002 | 217 | 0.200 |
Why?
| | Hip Fractures | 1 | 2003 | 75 | 0.200 |
Why?
| | Thyroid Gland | 1 | 2002 | 83 | 0.190 |
Why?
| | Methimazole | 1 | 2020 | 6 | 0.190 |
Why?
| | Myxedema | 1 | 2020 | 1 | 0.180 |
Why?
| | Absorptiometry, Photon | 3 | 2009 | 221 | 0.170 |
Why?
| | Diet | 1 | 2007 | 1072 | 0.170 |
Why?
| | Mass Screening | 3 | 2020 | 1024 | 0.170 |
Why?
| | Risk Factors | 5 | 2020 | 8699 | 0.170 |
Why?
| | Treatment Failure | 1 | 2020 | 332 | 0.170 |
Why?
| | Female | 16 | 2020 | 59931 | 0.160 |
Why?
| | Physical Examination | 1 | 2020 | 222 | 0.160 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1405 | 0.160 |
Why?
| | Reference Values | 1 | 2020 | 744 | 0.160 |
Why?
| | Triiodothyronine, Reverse | 1 | 2018 | 2 | 0.160 |
Why?
| | Thyroid Function Tests | 1 | 2018 | 11 | 0.160 |
Why?
| | Practice Patterns, Physicians' | 2 | 2006 | 1180 | 0.160 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2020 | 293 | 0.150 |
Why?
| | Hypoglycemia | 2 | 2016 | 386 | 0.150 |
Why?
| | Parathyroid Hormone | 2 | 2008 | 95 | 0.140 |
Why?
| | Biomarkers | 2 | 2020 | 3467 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2020 | 431 | 0.130 |
Why?
| | Referral and Consultation | 1 | 2020 | 646 | 0.130 |
Why?
| | Insulin Antibodies | 1 | 2016 | 102 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2020 | 863 | 0.130 |
Why?
| | Rituximab | 1 | 2016 | 149 | 0.120 |
Why?
| | Ambulatory Care | 2 | 2008 | 479 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 220 | 0.110 |
Why?
| | Aged | 9 | 2016 | 19255 | 0.110 |
Why?
| | Pregnancy | 3 | 2020 | 5550 | 0.110 |
Why?
| | Case-Control Studies | 1 | 2020 | 3023 | 0.110 |
Why?
| | Sex Factors | 2 | 2012 | 1737 | 0.110 |
Why?
| | Diabetes Complications | 1 | 2015 | 212 | 0.110 |
Why?
| | Age Factors | 2 | 2012 | 2907 | 0.110 |
Why?
| | Autoimmune Diseases | 1 | 2016 | 395 | 0.100 |
Why?
| | Thyroid Crisis | 1 | 2012 | 7 | 0.100 |
Why?
| | Aged, 80 and over | 3 | 2008 | 6419 | 0.100 |
Why?
| | Postpartum Thyroiditis | 1 | 2011 | 1 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 246 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2020 | 12608 | 0.100 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 511 | 0.090 |
Why?
| | Drug Interactions | 1 | 2012 | 347 | 0.090 |
Why?
| | Liver Diseases | 1 | 2012 | 263 | 0.090 |
Why?
| | Risk | 1 | 2012 | 819 | 0.080 |
Why?
| | Colorado | 4 | 2009 | 4116 | 0.080 |
Why?
| | Adipokines | 1 | 2009 | 43 | 0.080 |
Why?
| | Male | 10 | 2016 | 55967 | 0.080 |
Why?
| | Obesity | 2 | 2015 | 2517 | 0.080 |
Why?
| | Kidney Diseases | 1 | 2012 | 354 | 0.080 |
Why?
| | Community-Institutional Relations | 1 | 2009 | 89 | 0.080 |
Why?
| | Raloxifene Hydrochloride | 1 | 2008 | 13 | 0.080 |
Why?
| | Patient Care | 1 | 2008 | 103 | 0.080 |
Why?
| | Self Administration | 1 | 2008 | 124 | 0.080 |
Why?
| | Diphosphonates | 1 | 2008 | 51 | 0.070 |
Why?
| | Pharmaceutical Services | 1 | 2008 | 79 | 0.070 |
Why?
| | Pilot Projects | 2 | 2009 | 1377 | 0.070 |
Why?
| | Professional Role | 1 | 2008 | 153 | 0.070 |
Why?
| | Women's Health | 1 | 2009 | 271 | 0.070 |
Why?
| | Nutrition Policy | 1 | 2007 | 54 | 0.070 |
Why?
| | Life Style | 1 | 2009 | 429 | 0.070 |
Why?
| | Phosphorus | 1 | 2007 | 81 | 0.070 |
Why?
| | Insulin Lispro | 1 | 2006 | 35 | 0.070 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2015 | 1200 | 0.070 |
Why?
| | Nonprescription Drugs | 1 | 2007 | 68 | 0.070 |
Why?
| | Serum Albumin | 1 | 2007 | 135 | 0.070 |
Why?
| | Body Composition | 1 | 2009 | 580 | 0.060 |
Why?
| | Creatinine | 1 | 2007 | 430 | 0.060 |
Why?
| | Quality of Health Care | 1 | 2009 | 576 | 0.060 |
Why?
| | Patient Compliance | 1 | 2008 | 524 | 0.060 |
Why?
| | Middle Aged | 6 | 2015 | 27014 | 0.060 |
Why?
| | Outpatients | 1 | 2007 | 330 | 0.060 |
Why?
| | Fractures, Bone | 1 | 2009 | 372 | 0.060 |
Why?
| | Thyroid Nodule | 1 | 2003 | 37 | 0.060 |
Why?
| | Densitometry | 1 | 2003 | 29 | 0.050 |
Why?
| | Inpatients | 1 | 2006 | 380 | 0.050 |
Why?
| | Hospitals, University | 1 | 2003 | 172 | 0.050 |
Why?
| | Health Services for the Aged | 1 | 2003 | 70 | 0.050 |
Why?
| | Medical Records | 1 | 2003 | 157 | 0.050 |
Why?
| | Exons | 1 | 2002 | 300 | 0.050 |
Why?
| | Biopsy, Needle | 1 | 2002 | 183 | 0.050 |
Why?
| | Calcium | 1 | 2007 | 1103 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2009 | 1098 | 0.050 |
Why?
| | Prevalence | 1 | 2007 | 2265 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2009 | 4438 | 0.040 |
Why?
| | Adenoma | 1 | 2002 | 187 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2008 | 4440 | 0.040 |
Why?
| | Base Sequence | 1 | 2002 | 2114 | 0.040 |
Why?
| | Exercise | 1 | 2009 | 1609 | 0.040 |
Why?
| | Amino Acid Sequence | 1 | 2002 | 2000 | 0.040 |
Why?
| | Surveys and Questionnaires | 2 | 2015 | 4668 | 0.040 |
Why?
| | Molecular Sequence Data | 1 | 2002 | 2790 | 0.040 |
Why?
| | Risk Assessment | 1 | 2006 | 2987 | 0.040 |
Why?
| | Patient Discharge | 1 | 2003 | 770 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2002 | 1048 | 0.030 |
Why?
| | Prospective Studies | 1 | 2007 | 6264 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2016 | 500 | 0.020 |
Why?
| | Adult | 3 | 2015 | 30726 | 0.020 |
Why?
| | Resistin | 1 | 2009 | 12 | 0.020 |
Why?
| | Severity of Illness Index | 2 | 2009 | 2578 | 0.020 |
Why?
| | Biological Factors | 1 | 2009 | 37 | 0.020 |
Why?
| | Medical Audit | 1 | 2008 | 75 | 0.020 |
Why?
| | Hip Joint | 1 | 2009 | 131 | 0.020 |
Why?
| | Leptin | 1 | 2009 | 211 | 0.020 |
Why?
| | Adiponectin | 1 | 2009 | 214 | 0.020 |
Why?
| | Lumbar Vertebrae | 1 | 2009 | 217 | 0.020 |
Why?
| | Body Mass Index | 1 | 2015 | 1971 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2015 | 1078 | 0.020 |
Why?
| | Program Evaluation | 1 | 2008 | 836 | 0.010 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2009 | 1137 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2016 | 9159 | 0.010 |
Why?
| | Lung | 1 | 2009 | 3673 | 0.010 |
Why?
|
|
McDermott's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|